PUS7L

Across TCGA pan-cancer cohorts, PUS7L mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PUS7L data layer compared with 29 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PUS7L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PUS7L expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

GBM, CCRCC, and LSCC are the cancer types where PUS7L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.275	0.478	.013	9	view →
CCRCC	OS	Quartile	III,IV	0.428	0.782	.014	1	view →
LSCC	OS	Median	All	1.000	0.800	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PUS7L–GBM (DFS)

Open the GBM breakdown →